BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23288489)

  • 1. Prospective evaluation of B-type natriuretic peptide concentrations and the risk of type 2 diabetes in women.
    Everett BM; Cook NR; Chasman DI; Magnone MC; Bobadilla M; Rifai N; Ridker PM; Pradhan AD
    Clin Chem; 2013 Mar; 59(3):557-65. PubMed ID: 23288489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of B-type Natriuretic Peptides to Predict Cardiovascular Events in Women (from the Women's Health Study).
    Everett BM; Ridker PM; Cook NR; Pradhan AD
    Am J Cardiol; 2015 Aug; 116(4):532-7. PubMed ID: 26081066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-type natriuretic peptides improve cardiovascular disease risk prediction in a cohort of women.
    Everett BM; Berger JS; Manson JE; Ridker PM; Cook NR
    J Am Coll Cardiol; 2014 Oct; 64(17):1789-97. PubMed ID: 25443700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population.
    Suthahar N; Meijers WC; Ho JE; Gansevoort RT; Voors AA; van der Meer P; Bakker SJL; Heymans S; van Empel V; Schroen B; van der Harst P; van Veldhuisen DJ; de Boer RA
    Eur J Heart Fail; 2018 Aug; 20(8):1205-1214. PubMed ID: 29855124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
    Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Christersson C; Ezekowitz J; Gersh BJ; Hanna M; Hohnloser S; Horowitz J; Huber K; Hylek EM; Lopes RD; McMurray JJ; Granger CB
    J Am Coll Cardiol; 2013 Jun; 61(22):2274-84. PubMed ID: 23563134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations in hemodialysis patients: prognostic value of baseline and follow-up measurements.
    Gutiérrez OM; Tamez H; Bhan I; Zazra J; Tonelli M; Wolf M; Januzzi JL; Chang Y; Thadhani R
    Clin Chem; 2008 Aug; 54(8):1339-48. PubMed ID: 18539645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
    Januzzi JL; Xu J; Li J; Shaw W; Oh R; Pfeifer M; Butler J; Sattar N; Mahaffey KW; Neal B; Hansen MK
    J Am Coll Cardiol; 2020 Nov; 76(18):2076-2085. PubMed ID: 33121714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in N-terminal pro-B-type natriuretic peptide and incidence of diabetes: The Multi-Ethnic Study of Atherosclerosis (MESA).
    Sanchez OA; Duprez DA; Bahrami H; Peralta CA; Daniels LB; Lima JA; Maisel A; Folsom AR; Jacobs DR
    Diabetes Metab; 2015 Nov; 41(5):378-86. PubMed ID: 26047677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.
    Wolsk E; Claggett B; Pfeffer MA; Diaz R; Dickstein K; Gerstein HC; Lawson FC; Lewis EF; Maggioni AP; McMurray JJV; Probstfield JL; Riddle MC; Solomon SD; Tardif JC; Køber L
    J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28554908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of midregional pro-A-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in patients with stable coronary heart disease followed over 8 years.
    Karakas M; Jaensch A; Breitling LP; Brenner H; Koenig W; Rothenbacher D
    Clin Chem; 2014 Nov; 60(11):1441-9. PubMed ID: 25139456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes.
    Tarnow L; Gall MA; Hansen BV; Hovind P; Parving HH
    Diabetologia; 2006 Oct; 49(10):2256-62. PubMed ID: 16937127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes Mellitus.
    Malachias MVB; Jhund PS; Claggett BL; Wijkman MO; Bentley-Lewis R; Chaturvedi N; Desai AS; Haffner SM; Parving HH; Prescott MF; Solomon SD; De Zeeuw D; McMurray JJV; Pfeffer MA
    J Am Heart Assoc; 2020 Oct; 9(19):e017462. PubMed ID: 32964800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opposing Associations of NT-proBNP With Risks of Diabetes and Diabetes-Related Complications.
    Birukov A; Eichelmann F; Kuxhaus O; Polemiti E; Fritsche A; Wirth J; Boeing H; Weikert C; Schulze MB
    Diabetes Care; 2020 Dec; 43(12):2930-2937. PubMed ID: 32816995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic role of N-terminal pro-brain natriuretic peptide in asymptomatic hypertensive and diabetic patients in primary care: impact of age and gender : Results from the PROBE-HF study.
    Ballo P; Betti I; Barchielli A; Balzi D; Castelli G; De Luca L; Gheorghiade M; Zuppiroli A
    Clin Res Cardiol; 2016 May; 105(5):421-31. PubMed ID: 26547915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum N-terminal Pro-brain Natriuretic Peptide Level is Associated with the Development of Chronic Kidney Diseases in Patients with Type 2 Diabetes.
    Sawada R; Hashimoto Y; Senmaru T; Tanaka M; Ushigome E; Yamazaki M; Fukui M
    Endocr Metab Immune Disord Drug Targets; 2018; 18(6):590-595. PubMed ID: 29697035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic association analysis of the cardiovascular biomarker: N-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP).
    Yang Y; Zmuda JM; Wojczynski MK; Thyagarajan B; Christensen K; Cvejkus RK; Kuipers AL
    PLoS One; 2021; 16(3):e0248726. PubMed ID: 33720941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes.
    Rørth R; Jhund PS; Kristensen SL; Desai AS; Køber L; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    Eur J Heart Fail; 2019 Jan; 21(1):40-49. PubMed ID: 30537261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining the use of amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the prognosis of hospitalized heart failure patients.
    Wang Y; Zhang R; Huang Y; Zhai M; Zhou Q; An T; Huang Y; Zhao X; Tian P; Zhang Y; Zhang J
    Clin Chim Acta; 2019 Apr; 491():8-14. PubMed ID: 30594544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of midregional pro-A-type natriuretic peptide and the N-terminal pro-B-type natriuretic peptide for predicting mortality and cardiovascular events.
    van Hateren KJ; Alkhalaf A; Kleefstra N; Groenier KH; de Jong PE; de Zeeuw D; Gans RO; Struck J; Bilo HJ; Gansevoort RT; Bakker SJ
    Clin Chem; 2012 Jan; 58(1):293-7. PubMed ID: 21948291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
    Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
    Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.